Last updated on September 2018

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment


Brief description of study

Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.

Detailed Study Description

This is a Phase 1, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors with varying degrees of renal impairment. The study is conducted in 2 parts: the Pharmacokinetic Part (Cycle 1) and the Extension Part (Cycles 2 and beyond). Patients may continue to receive treatment with TAS-102 during the study extension part only after completion of the Pharmacokinetic Part.

Clinical Study Identifier: NCT02301117

Find a site near you

Start Over

Phoenix Clinical Site

Phoenix, AZ United States
  Connect »

Duarte Clinical Site

Duarte, CA United States
  Connect »

Santa Monica Clinical Site

Santa Monica, CA United States
  Connect »

Gainesville Clinical Site

Gainesville, FL United States
  Connect »

Baltimore Clinical Site

Baltimore, MD United States
  Connect »

Boston Clinical Site

Boston, MA United States
  Connect »

Cleveland Clinical Site

Cleveland, OH United States
  Connect »

Pittsburgh Clinical Site

Pittsburgh, PA United States
  Connect »

Dallas Clinical Site

Dallas, TX United States
  Connect »